Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia

Exclusion Criteria

• •Patients who are currently receiving any other investigational agents
• •Patients who have received more than one chemotherapeutic regimen in metastatic setting
• •Patients with CNS metastases
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• •Patients with unresolved grade 3/4 adverse effects of prior therapy at time of enrollment
• •Subjects with history of hypersensitivity to compounds of similar chemical or biologic composition to Xilonix or Onivyde
• •Women who are pregnant or breastfeeding
• •Dementia or altered mental status that would prohibit the understanding or rendering of informed consent
• •Patients with known Dihydropyrimidine dehydrogenase deficiency (DPD deficiency)
• •Patients known to be UGT1A1\*28 allele homozygous
• •Patients who have had a live vaccine within 3 months of enrollment